020: Pathogen Inactivation with Jeff McCullough
Blood Bank Guy Essentials Podcast
00:00
The Cost of Pathogen and Activation in Transfusion Medicine
Churumo has data mostly from a French study showing that the same thing, as I mentioned, about intercept platelets. They also found the same thing that the post transfusion counts are a little bit lower. Churumo is quite far along in preparing to open their definitive phase three clinical trial in the U.S., which of course they hope will lead to a approval of mirror-soled platelets in the US. But that's going to be three years or more off because the trial hasn't even started yet. And it will take a couple of years to do that trial.
Transcript
Play full episode
